Patients with ESCC who received pembrolizumab plus chemotherapy and had a PD-L1 expression of 10 or more achieved a median survival of 13.9 months, compared to 8.8 months with traditional chemotherapy alone. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.